glp-1 for weight loss side effects and Loss: The Revolutionary Treatment Transforming Obesity Care in 2026 New Study Reveals Genetic Predictors

Selected Clinical Trial Activity Epithalon is a research-grade compound that has been studied in laboratory settings but has not undergone full clinical development

In the New England Journal of Medicine, Garvey and colleagues [5] report the results of the REDEFINE 1 trial, a 68-week, phase 3a double-blind, placebo-controlled and active-controlled trial evaluating the efficacy and safety of coadministered cagrilintide and semaglutide in adults with obesity [body mass index (BMI) 30 kg/m 2 ] or overweight (BMI 27 kg/m 2 ) with at least one weight-related comorbidity

Its hepatoprotective action may occur by cytokine-mediated mechanisms as well as GSH replenishment (21)

& Scofield, M

Steinhauser, C., Seifert, G

doi: 10.1016/j.orcp.2026.01.002 74 StanleyTLFourmanLTFeldpauschMNPurdyJZhengIPanCSet al